AI Article Synopsis
Article Abstract
Allergic diseases are some of the most commonly encountered problems in clinical practice. Drugs such as corticosteroids and antihistamines can provide effective symptomatic relief, but do not alter the course of the disease. Specific immunotherapy (SIT) was first used to treat pollen allergy in 1911, and has since evolved into an effective treatment for allergic rhinitis and asthma. SIT has been shown in clinical studies to reduce symptoms and medication use in patients with allergic rhinitis and asthma. Recent studies also showed that the therapeutic benefit is long-lasting after the completion of three to five years of treatment. SIT can also effectively reduce the risk of developing asthma and new allergic sensitizations in children with allergic rhinitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378232 | PMC |
| http://dx.doi.org/10.3978/j.issn.2072-1439.2011.07.03 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children.
JAMA Pediatr
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.
Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.
Gut microbiota, immune cells, and chronic sinusitis: A Mendelian randomization analysis.
Medicine (Baltimore)
January 2025
The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Allergic rhinitis (AR) is a common allergic inflammatory disease that affects the upper respiratory tract. Although previous research suggests a potential association between gut microbiota alterations and AR, the causal relationship remains unclear. This study employs Mendelian randomization (MR) to reduce confounding factors and reverse causality.
View Article and Find Full Text PDFPharmacokinetics and Bioequivalence of 2 Products of Fluticasone Propionate Nasal Spray in Healthy Chinese Subjects.
Clin Pharmacol Drug Dev
January 2025
Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, People's Republic of China.
Fluticasone propionate nasal spray is widely regarded as a first-line therapy for allergic rhinitis. To establish bioequivalence between the test and reference products of fluticasone propionate nasal spray, an open-label, randomized, single-dose, and 2-sequence crossover study was conducted on 84 healthy Chinese subjects under fasting conditions to determine the pharmacokinetic bioequivalence of the 2 products. Following a single-dose administration (200 µg) of fluticasone propionate nasal spray, pharmacokinetic parameters, including maximum plasma concentration, area under the concentration-time curve from administration to the last measurable concentration, and area under the concentration-time curve from administration to infinity, exhibited similarity between the 2 products, with 90% confidence intervals for the test/reference ratios falling within the bioequivalence range of 80%-125%.
View Article and Find Full Text PDFEfficacy of Using Photobiomodulation Therapy in Allergic Rhinitis: A Placebo-Controlled Randomized Clinical Trial.
Int Forum Allergy Rhinol
January 2025
Universidade Estadual de Londrina, Londrina, Brazil.
Background: Recent studies have extensively explored new non-invasive and side-effect-free therapeutic strategies for the treatment of allergic rhinitis (AR). Photobiomodulation therapy (PBMT) utilizes photons from the red to infrared spectrum to modulate biological processes, exhibiting anti-inflammatory and regenerative properties. The objective of our study was to evaluate the efficacy of PBMT in patients with AR.
View Article and Find Full Text PDFDevelopment and validation of a nomogram for predicting cough variant asthma diagnosis.
BMC Pulm Med
January 2025
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China.
Background: Cough variant asthma (CVA) is a specific type of asthma characterized by chronic cough as the sole or predominant symptom. Accurate diagnosis is crucial for effective treatment, yet bronchial provocation test is not always feasible in clinical settings. To identify independent predictors of CVA diagnosis, we developed a nomogram for predicting CVA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!